fbpx

Nearly 1 million people will have Parkinson’s in the U.S.

By 2020.

More than 10 million people worldwide are living with PD.

It’s time to stop Parkinson’s disease by working together, collaboratively, across platforms, without silos.

 


A DREAM TEAM

OF MIT RESEARCHERS IS WORKING TO 
TO MAKE THAT HAPPEN.

Professors Robert Langer, Ann Graybiel and Michael Cima lead world-renowned biomedical research labs at MIT, and all three have a proven track record in innovating therapeutic avenues for complex diseases including Parkinson’s. They have developed one of the world’s smallest drug delivery systems and they have also created an integrated brain implant platform capable of monitoring neurochemical levels in the brain – important for monitoring disease development and the efficacy of any therapy.  These cutting-edge, nanotechnology based tools, in concert with arguably some of the best researchers in the world, are reasons alone why this initiative is truly a revolution in Parkinson’s research.

The Parkinson’s Community
is Ready for a
Revolution
in Research.

NOT FAR FROM LEXINGTON AND CONCORD,
A DREAM TEAM

OF MIT RESEARCHERS IS POISED
TO MAKE THAT HAPPEN.

Professors Robert Langer, Ann Graybiel and Michael Cima lead world-renowned biomedical research labs at MIT, and all three have a proven track record in innovating therapeutic avenues for complex diseases including Parkinson’s. They have developed one of the world’s smallest drug delivery systems and they have also created an integrated brain implant platform capable of monitoring neurochemical levels in the brain – important for monitoring disease development and the efficacy of any therapy.  These cutting-edge, nanotechnology based tools, in concert with arguably some of the best researchers in the world, are reasons alone why this initiative is truly a revolution in Parkinson’s research.

Collaborative Teams Can Yield Huge Results: MIT Leads the Way


In December 2018, two decades of research starting in the Langer Lab at MIT resulted in FDA approval of Inbrija, the
first approved inhaled levodopa powder for Parkinson’s patients.

A major push is now needed to take
therapeutics for Parkinson’s to the next level.

THE TIME IS NOW

 

Using nanotechnology and the resources of MIT – one of the world’s leading Universities – plus unique tools, and a team of research scientists that have consistently delivered results:

 

This MIT Research Team Delivers Consistent Results

This world-class team has done it before – and now has Parkinson’s Disease in its sights, working to close the gap between idea, solution and implementation at a potentially record pace – using nanotechnology in a multi-disciplinary, collaborative research project that is sparking new findings and exciting outcomes – with your help.

PROFESSOR ROBERT LANGER

BIOMEDICAL ENGINEERING

PROFESSOR ANN GRAYBIEL

NEUROSCIENCE

PROFESSOR MICHAEL CIMA

DRUG DELIVERY AND DEVICE DESIGN

World-renowned neuroscientists at MIT’s McGovern Institute for Brain Research are meeting two GREAT CHALLENGES OF MODERN SCIENCE:

1. Understanding how
the brain works

2. Discovering new ways to
prevent or treat brain disorders

World-renowned neuroscientists at MIT’s McGovern Institute for Brain Research are meeting two GREAT CHALLENGES OF MODERN SCIENCE:

1. Understanding How
the Brain Works

2. Discovering New Ways to
Prevent or Treat Brain Disorders

MIT PARKINSON’S DISEASE RESEARCH INITIATIVE

NANOTECHNOLOGY-BASED

PROVEN RESULTS

COLLABORATION, TALENT, CULTURE

Working With Urgency:

The BRAIN DISORDERS & PARKINSON’S COMMUNITIES ARE READY FOR NEW TOOLS IN THE FIGHT AGAINST THESE DEGENERATIVE DISEASES.

This team’s toolbox is already impressive.  Learn about how they are already making a difference – here.

Working With Urgency:

The BRAIN DISORDERS & PARKINSON’S COMMUNITIES ARE READY FOR NEW TOOLS IN THE FIGHT AGAINST THESE DEGENERATIVE DISEASES.

This team’s tToolbox is already impressive.  Learn about how they are already making a difference – here.

WHO WE ARE

CURE NOW:PD

WE’RE PEOPLE WITH PD – READY FOR A CURE: NOW

Cure Now: PD is focused on finding disease-modifying treatments, and a Cure: Now. 

 

WHAT WE DO

The Mission of Cure Now: PD is to find the cure for Parkinson’s by funding cutting-edge research and establishing collaborative relationships with leading research institutions and labs that can lead to breakthroughs via sharing of ideas, methods and processes.

TAKE ACTION

Cure Now: PD is dedicated to working collaboratively with Parkinson’s groups and communities to fund out of the box, cutting-edge research through fundraising and community engagement.
Join us today and make an impact.